EUCTR2012-002067-10-NL进行中（未招募）不适用
Mesenchymal stromal cells for treatment of drug resistantpediatric Juvenile idiopathic arthritis - MSC-JIA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients (4-18 years of age) diagnosed with juvenile idiopathic arthritis according to the ILAR-criteria with active arthritis resistant to intra-articular steroids and systemic use of methotrexate and for whom no on-label indication exists for (not yet used) biologicals. The patient is followed for adverse events via the Pharmachild database.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 6
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concurrent use of biological response modifiers.
- •Concurrent infection, febrile illness or malignancy.
研究者
相似试验
招募中
不适用
Mesenchymal stromal cells for treatment of drug resistantpediatric juvenile idiopathic arthritisjuvenile idiopathic arthritisNL-OMON21350niversity Medical Center Utrecht6
进行中（未招募）
不适用
Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial - MSC-GvHDGraft versus Host disease GvHD steroid resistantEUCTR2008-007869-23-ITAZIENDA OSPEDALIERA SAN GERARDO DI MONZA
进行中（未招募）
不适用
se of mesenchymal cells for the treatment of patients with respiratory syndrome caused by new coronavirusRBR-3fz9yrPaulo Roberto Slud Brofman
进行中（未招募）
不适用
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
终止
1 期
se of mesenchymal stromal cells for Graft-versus-host disease after stem cell transplantatioGraft vs Host DiseaseT86.0RBR-7s99ksfHospital de Clínicas da Universidade Federal do Paraná - HCUFPR